全文获取类型
收费全文 | 1495篇 |
免费 | 136篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 42篇 |
妇产科学 | 10篇 |
基础医学 | 209篇 |
口腔科学 | 7篇 |
临床医学 | 170篇 |
内科学 | 481篇 |
皮肤病学 | 13篇 |
神经病学 | 80篇 |
特种医学 | 66篇 |
外科学 | 129篇 |
综合类 | 24篇 |
预防医学 | 182篇 |
眼科学 | 18篇 |
药学 | 83篇 |
肿瘤学 | 86篇 |
出版年
2021年 | 13篇 |
2020年 | 15篇 |
2019年 | 16篇 |
2018年 | 34篇 |
2017年 | 12篇 |
2016年 | 36篇 |
2015年 | 24篇 |
2014年 | 35篇 |
2013年 | 42篇 |
2012年 | 78篇 |
2011年 | 86篇 |
2010年 | 55篇 |
2009年 | 29篇 |
2008年 | 97篇 |
2007年 | 90篇 |
2006年 | 80篇 |
2005年 | 93篇 |
2004年 | 68篇 |
2003年 | 75篇 |
2002年 | 51篇 |
2001年 | 35篇 |
2000年 | 34篇 |
1999年 | 39篇 |
1998年 | 21篇 |
1997年 | 11篇 |
1996年 | 13篇 |
1995年 | 15篇 |
1993年 | 10篇 |
1992年 | 25篇 |
1991年 | 27篇 |
1990年 | 26篇 |
1989年 | 25篇 |
1988年 | 20篇 |
1987年 | 19篇 |
1986年 | 8篇 |
1985年 | 18篇 |
1984年 | 17篇 |
1983年 | 18篇 |
1982年 | 11篇 |
1979年 | 16篇 |
1978年 | 16篇 |
1977年 | 10篇 |
1976年 | 16篇 |
1974年 | 17篇 |
1973年 | 11篇 |
1972年 | 18篇 |
1971年 | 9篇 |
1970年 | 11篇 |
1969年 | 9篇 |
1968年 | 16篇 |
排序方式: 共有1631条查询结果,搜索用时 31 毫秒
31.
Plasma adrenomedullin and obstructive sleep apnea 总被引:2,自引:0,他引:2
Wolk R Svatikova A Otto ME Hoffmann MS Duenwald CJ Somers VK 《American journal of hypertension》2004,17(1):74-76
BACKGROUND: Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances. METHODS: Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls. RESULTS: Baseline ADM levels were similar in the OSA and control groups (28.7 +/- 6.7 v 27.7 +/- 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure. CONCLUSIONS: OSA does not exert any significant acute or chronic effects on plasma ADM levels. 相似文献
32.
33.
Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance 总被引:1,自引:0,他引:1
Peripheral levels of basal and tolbutamide-induced somatostatin have been measured in patients with diabetes or impaired glucose tolerance (IGT) and compared with those in normal individuals. Basal somatostatin was significantly higher in patients with Type 1 diabetes than in age-matched control subjects. This increase was most pronounced at diagnosis, and appeared to be related to metabolic control in insulin-treated patients. No increase was noted in patients with Type 2 diabetes or with IGT. Intravenous bolus injection of tolbutamide enhanced peripheral somatostatin levels in healthy volunteers in a biphasic manner. Patients with IGT also exhibited a biphasic response but the amplitude of the first phase was higher. No secretory response was detected in 27/29 Type 1 diabetic patients at diagnosis; a somatostatin response to tolbutamide became detectable again in Type 1 patients with normalization of their basal somatostatin levels but was then paradoxically related to poor blood glucose control. In Type 2 diabetes, basal somatostatin levels were similar to age-matched control subjects, but decreased upon intravenous tolbutamide administration. 相似文献
34.
Obstructive sleep apnea and hypertension 总被引:4,自引:0,他引:4
There is growing evidence of a causal relationship between obstructive sleep apnea (OSA) and hypertension. Untreated OSA may
have direct and deleterious effects on cardiovascular function and structure through several mechanisms, including sympathetic
activation, oxidative stress, inflammation, and endothelial dysfunction. OSA may contribute to or augment elevated blood pressure
levels in a large proportion of the hypertensive patient population. It is important to consider OSA in the differential diagnosis
of hypertensive patients who are obese. OSA should be especially considered in those hypertensive patients who respond poorly
to combination therapy with antihypertensive medications. 相似文献
35.
Jolien Suurmond Jurgen van Heemst Jacqueline van Heiningen Annemarie L. Dorjée Marco W. Schilham Feddo B. van der Beek Tom W.J. Huizinga Annemie J.M. Schuerwegh René E.M. Toes 《European journal of immunology》2013,43(7):1758-1768
Mast cells (MCs) are immune cells residing in tissues where pathogens are first encountered. It has been indicated that MCs might also be involved in setting the outcome of T‐cell responses. However, little is known about the capacity of human MCs to express MHC class II and/or to capture and present antigens to CD4+ T cells. To study the T‐cell stimulatory potential of human MCs, CD34+ stem cell derived MCs were generated. These cells expressed HLA‐DR when stimulated with IFN‐γ, and, importantly, presented peptide and protein for activation of antigen‐specific CD4+ T cells. The interplay between MC and T cell led to increased HLA‐DR expression on MCs. MCs were present in close proximity to T cells in tonsil and expressed HLA‐DR and CD80, indicating their ability to present antigens to CD4+ T cells in T‐cell areas of human LNs. Our data show that MCs can present native antigens to human CD4+ T cells and that HLA‐DR expressing MCs are present in tonsil tissue, indicating that human MCs can directly activate T cells and provide a rationale to study the potential of MCs to prime and/or skew human T‐cell responses. 相似文献
36.
Kato M Hisatome I Tomikura Y Kotani K Kinugawa T Ogino K Ishida K Igawa O Shigemasa C Somers VK 《The American journal of cardiology》2005,96(11):1576-1578
Hyperuricemia has been associated with an increased risk for cardiovascular disease and increased mortality. However, the biologic mechanisms that link elevated serum uric acid to cardiovascular disease are uncertain. This study tested the hypothesis that elevated serum uric acid is associated with impaired endothelial function in hyperuricemic patients without any overt cardiovascular disease. Seventeen male patients with hyperuricemia (mean age 42+/-4 years) and 9 control subjects (mean age 45+/-5 years) were studied. All subjects were nonsmokers. All patients had never been treated for hyperuricemia, were on no medications, and were free of any other known diseases. Endothelial function was evaluated by flow-mediated dilation measured by ultrasound. Flow-mediated dilation was significantly impaired in patients with hyperuricemia (4.0+/-0.7%) compared with control subjects (6.4+/-0.8%) (p=0.044). Flow-mediated dilation correlated inversely with uric acid levels (r=-0.4, p=0.05). Nitrate-induced dilation was 12.3+/-1.0% in patients with hyperuricemia and 11.8+/-2.3% in control subjects (p=0.82). Impaired endothelial-dependent vasodilation is present in hyperuricemic patients even in the absence of any overt cardiovascular disease. The elevated serum uric acid, per se, may constitute a novel risk factor for endothelial dysfunction. 相似文献
37.
38.
Scherptong RW Henkens IR Kapel GF Swenne CA van Kralingen KW Huisman MV Schuerwegh AJ Bax JJ van der Wall EE Schalij MJ Vliegen HW 《Journal of electrocardiology》2012,45(3):312-318
PurposeThe aim of this study was to investigate the use of the electrocardiogram-derived ventricular gradient, projected on the x-axis (VGx), for detection of pulmonary hypertension (PH) and for prediction of all-cause mortality in PH patients.MethodsIn patients referred for PH screening (n = 216), the VGx was calculated semiautomatically from the electrocardiogram and was defined as abnormal when less than 24 mV·ms. The VGx of PH patients was compared with the VGx of patients without PH. The association between a reduced VGx and mortality was investigated in PH patients.ResultsPatients with PH (n = 117) had a significantly reduced VGx: 14 ± 27 vs 45 ± 23 mV·ms, P < .001. Furthermore, a severely reduced VGx (<0 mV·ms) was associated with increased mortality in PH patients: hazard ratio, 1.025 (95% confidence interval, 1.006-1.045; P = .012) per mV·ms VGx decrease.ConclusionReduced VGx is associated with the presence of PH and, more importantly, within PH patients, a severely reduced VGx predicts mortality. 相似文献
39.
Singh P Peterson TE Sert-Kuniyoshi FH Glenn JA Davison DE Romero-Corral A Pusalavidyasagar S Jensen MD Somers VK 《Circulation research》2012,111(5):599-603
Rationale: The link between obesity, hyperleptinemia, and development of cardiovascular disease is not completely understood. Increases in leptin have been shown to impair leptin signaling via caveolin-1-dependent mechanisms. However, the role of hyperleptinemia versus impaired leptin signaling in adipose tissue is not known. Objective: To determine the presence and significance of leptin-dependent increases in adipose tissue caveolin-1 expression in humans. Methods and Results: We designed a longitudinal study to investigate the effects of increases in leptin on adipose tissue caveolin-1 expression during weight gain in humans. Ten volunteers underwent 8 weeks of overfeeding, during which they gained an average weight of 4.1±1.4 kg, with leptin increases from 7±3.8 to 12±5.7 ng/mL. Weight gain also resulted in changes in adipose tissue caveolin-1 expression, which correlated with increases in leptin (rho=0.79, P=0.01). In cultured human white preadipocytes, leptin increased caveolin-1 expression, which in turn impaired leptin cellular signaling. Functionally, leptin decreased lipid accumulation in differentiating human white preadipocytes, which was prevented by caveolin-1 overexpression. Further, leptin decreased perilipin and fatty acid synthase expression, which play an important role in lipid storage and biogenesis. Conclusions: In healthy humans, increases in leptin, as seen with modest weight gain, may increase caveolin-1 expression in adipose tissue. Increased caveolin-1 expression in turn impairs leptin signaling and attenuates leptin-dependent lowering of intracellular lipid accumulation. Our study suggests a leptin-dependent feedback mechanism that may be essential to facilitate adipocyte lipid storage during weight gain. 相似文献
40.